DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Phase 2

Active, not recruiting

Conditions: Genitourinary Cancer
Adrenocortical Carcinoma
Non-urothelial Bladder
Non-urothelial Upper Tract
Penile Cancer
Non-adenocarcinoma Prostate Cancer
Refractory Germ-cell
High Grade Neuroendocrine Carcinoma/Small Cell Carcinoma

Interventions: Drug: Ipilimumab
Drug: Nivolumab

First Posted Date: 2017-11-07

Last Posted Date: 2024-02-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 100

Registration Number: NCT03333616

Locations: 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸
University of California, San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 3 locations

Physical Activity In Gastrointestinal Cancer

Not Applicable

Completed

Conditions: Metastatic Gastrointestinal Cancer
Physical Activity

Interventions: Other: Physical Activity Program

First Posted Date: 2017-11-06

Last Posted Date: 2020-03-12

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT03331406

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Other: Pre-test video education
Other: Traditional pre-test genetic counseling

First Posted Date: 2017-11-01

Last Posted Date: 2024-01-18

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 662

Registration Number: NCT03328091

Locations: 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL

Phase 1

Recruiting

Conditions: Leukemia

Interventions: Drug: Venetoclax
Drug: Standard Chemotherapy

First Posted Date: 2017-10-24

Last Posted Date: 2024-05-29

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 82

Registration Number: NCT03319901

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Intermountain LDS Hospital, Salt Lake City, Utah, United States

and more 2 locations

A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: Nivolumab
Drug: Cabozantinib

First Posted Date: 2017-10-20

Last Posted Date: 2021-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT03316586

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Pembrolizumab in Neoplasms or Lymphomas

Phase 2

Suspended

Conditions: Lymphoma
Histiocytic Sarcoma
Follicular Dendritic Cell Sarcoma
Interdigitating Dendritic Cell Sarcoma

Interventions: Drug: Pembrolizumab

First Posted Date: 2017-10-20

Last Posted Date: 2024-02-16

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 18

Registration Number: NCT03316573

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 1 locations

Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer

Phase 1

Completed

Conditions: Pancreatic Cancer

Interventions: Drug: Gemcitabine
Drug: Nab-paclitaxel
Drug: Ficlatuzumab

First Posted Date: 2017-10-20

Last Posted Date: 2021-08-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT03316599

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-type Cyclins or Amplification of CDK4 or CDK6

Phase 2

Recruiting

Conditions: Cancer

Interventions: Drug: Abemaciclib

First Posted Date: 2017-10-16

Last Posted Date: 2024-02-06

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 38

Registration Number: NCT03310879

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Ribociclib + PDR001 in Breast Cancer and Ovarian Cancer

Phase 1

Terminated

Conditions: Metastatic Hormone-Receptor-Positive (HR+) Breast Cancer
Metastatic Epithelial Ovarian Cancer
HER2-Negative Breast Cancer

Interventions: Drug: Ribociclib
Drug: PDR001
Drug: Fulvestrant

First Posted Date: 2017-09-27

Last Posted Date: 2022-03-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 33

Registration Number: NCT03294694

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Nurse Led Project to Introduce Hand Lettering as a Form of Creative Art Expression to Patients in an Ambulatory Oncology Setting

Not Applicable

Completed

Conditions: Anxiety

Interventions: Behavioral: Breathing and journaling exercise
Other: Art-therapy

First Posted Date: 2017-09-25

Last Posted Date: 2018-12-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT03291730

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy